DYNE THERAPEUTICS INC (DYN)
US26818M1080 - Common Stock
We assign a fundamental rating of 3 out of 10 to DYN. DYN was compared to 565 industry peers in the Biotechnology industry. DYN has a great financial health rating, but its profitability evaluates not so good. DYN has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year DYN has reported negative net income.
In the past year DYN has reported a negative cash flow from operations.
In the past 5 years DYN always reported negative net income.
DYN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -31.19%, DYN is doing good in the industry, outperforming 65.60% of the companies in the same industry.
DYN has a Return On Equity of -33.23%. This is in the better half of the industry: DYN outperforms 77.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.19% | ||
| ROE | -33.23% | ||
| ROIC | N/A |
ROA(3y)-77.62%
ROA(5y)-68.06%
ROE(3y)-121.86%
ROE(5y)-97.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for DYN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
DYN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DYN has been increased compared to 5 years ago.
DYN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 34.06 indicates that DYN is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 34.06, DYN belongs to the best of the industry, outperforming 96.08% of the companies in the same industry.
There is no outstanding debt for DYN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 34.06 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 26.63 indicates that DYN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 26.63, DYN belongs to the top of the industry, outperforming 97.68% of the companies in the same industry.
A Quick Ratio of 26.63 indicates that DYN has no problem at all paying its short term obligations.
DYN's Quick ratio of 26.63 is amongst the best of the industry. DYN outperforms 97.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 26.63 | ||
| Quick Ratio | 26.63 |
3. Growth
3.1 Past
The earnings per share for DYN have decreased by -5.59% in the last year.
EPS 1Y (TTM)-5.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
DYN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.89% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.99%
EPS Next 2Y9.1%
EPS Next 3Y5.74%
EPS Next 5Y18.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DYN. In the last year negative earnings were reported.
Also next year DYN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.1%
EPS Next 3Y5.74%
5. Dividend
5.1 Amount
No dividends for DYN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DYNE THERAPEUTICS INC
NASDAQ:DYN (11/22/2024, 8:00:00 PM)
After market: 29.69 0 (0%)29.69
-0.04 (-0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.98B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.19% | ||
| ROE | -33.23% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 26.63 | ||
| Quick Ratio | 26.63 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-5.59%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y22.99%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y